Navigation Links
Identified 2 new genes involved in the more aggressive prostate cancer
Date:5/13/2014

A study by the Columbia University Nova York, in collaboration with the Catalan Institute of Oncology , Belvitge Biomedical Research Institute (ICO-IDIBELL) has identified two new genes that lead to more aggressive forms of prostate cancer. The work done by Alvaro Aytes under the direction of Cory Abate-Shen , director of the Herbert Irving Comprehensive Cancer Center of the Columbia University, has been published in the latest issue of Cancer Cell.

Prostate cancer

Prostate cancer is the most common in men in Europe( accounts for 20% of all male tumors). The incidence is about 60 new cases per 100,000 inhabitants per year.

A tumor closely associated with old age, and most cases is diagnosed between 70 and 80 years. The progressive aging of the population has made it one of the tumors that has increased in recent decades. Survival is quite high: according to Oncology Master Plan, 84 % of patients are alive five years after diagnosis.

Identify high-risk patients

In a significant proportion of patients the prostate tumor has a not very aggressive behavior, which does not compromise the health and quality of life of the affected. Also, being a tumor that usually occurs in old age, often the person dies with the tumor but not as a result of this.

It is therefore necessary to develop tools to predict which prostate tumors are clinically relevant and potentially lethal. This would open the door to customize treatments and avoid certain therapies and , therefore, avoid side effects to patients that do not need it, further reducing healthcare costs.

Two new genes in the spotlight

The study published in Cancer Cell identified two genes, the FOXM1 and CENPF, if they are abnormally activated simultaneously, lead to more aggressive and life threatening forms of prostate cancer .

A new feature of the study is that computer algorithms were used to generate networks of interactions between molecules that are generated specifically in prostate cancer .

Currently they have launched preclinical studies to determine which treatments or combinations of drugs are more effective in combating abnormal activation of FOXM1 and CENPF genes. Also, in the near future, identifying the presence or absence of these biomarkers in an individual patient will provide a more effective and with fewer side effects individualized treatment.


'/>"/>

Contact: Arantxa Mena
amena@idibell.cat
0034-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert  

Related medicine news :

1. Predictors identified for rehospitalization among post-acute stroke patients
2. 2 repressor genes identified as essential for placental development
3. Possible new cancer treatment identified
4. Gene Behind Psoriasis Identified, Researchers Say
5. A microRNA prognostic marker identified in acute leukemia
6. Early biomarker for pancreatic cancer identified
7. The cells petrol pump is finally identified
8. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
9. New cerebellar ataxia gene identified in dogs
10. Misidentified and contaminated cell lines lead to faulty cancer science
11. Germ Culprits in Moldy, Water-Damaged Buildings Identified
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Identified 2 new genes involved in the more aggressive prostate cancer
(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: